Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure

NCT02558374 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.

NCT NCT02558374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02558374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
Lead sponsor
Aerie Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2015
Completion date
December 31, 2016
Enrollment
708 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open-angle glaucoma